Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
eNq1mG9v2jAQxt/zKaK8J+FPO6IpUG2s3ZBaldGiTXtTOclRzIKdnm1K9+nnELrB5KzU1BIvIA7PXXyPf3dKfLZe5t4KUFDO+n47aPkesJRnlN33/entRTPyzwaNeEFWZOe2XtAK2h3fS3MiRN8vV4MECBPB96vLT6D/D+gPGl7MkwWkcu8+JWkefCFifkWK8h4vXnGaeUuQc571/ULJzVUvFhJ1FoNHjj9FQVKIw+2V3dXF3cnu9TgsxQ5QVQLwkrB7o+gMrTRThQhMDomEe45PZun0rhP13rVakVUIKiYguMIUxkTOx8hXNIPMHInkAqyCzB6zG8BVDrIMYhQPF+lSWImTBVlP4GFkTvqDXh3KtWy2mu1e77TXbXWidu+0axUKd7bKbB79EGFx1+12O/oTzjCkywTViqakSfUXSRlNLOs05ihJ7qhCVAz3veYoDsLDi07IqChy8hQsRGG7VQSJXgbURHD3IOUT3KJmVK737B99pvI8fGXW0y1BHGVcAmrIFZM1ILmY2G7EkDMJ6/qK2rFPrrdepCDeTvYXZ2buj1WS09QWbxpACoScTkb1dHMFho9EwBTdkeEbZRl/FG9PnN0KO8q+2EDzP43zJIoi6+P0Q5uppu+cK+QFhJpEVBwDmBGb8WPRov1plnp2pxNjbgYinpIcakaipiVxtCOfJzhnnnd3nqoFo+jn81tbq3xVgE83m59GaZr1/xTZDscuGK+NWZv4621enfUDhuWTyHITFJpRMpeyEO/DcE5EUxC9UYE+Ry6Rv9Nx3Y3sTtp6NeZU4HSUelL1w8MrZXvoXmr6xw6y2/9vB2ZjDIkKjqhDxWdnFB2dvz2Y/06xztIe74HEXZjNxEkk5czV9KMSo+JxrUDXlV2ghsP1bEZr3qLU+jIOqzc4g0Yclm9vBo3fju33dg==
K7rymkVbvDZrvn0N
